Brainstorm cell therapeutics stock trading halted today

Fda advisory committee (adcom) meeting to review nurown® for als new york , sept. 27, 2023 /prnewswire/ -- brainstorm cell therapeutics inc. (nasdaq: bcli), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced that nasdaq has halted trading of the company's common stock.
BCLI Ratings Summary
BCLI Quant Ranking